Pharmafile Logo

News and Press Releases

New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment

Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and...

Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: June 14, 2024

Molecular Partners
info@molecularpartners.com
Wagistrasse 14 8952 Zurich-Schlieren Switzerland

KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy

Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma...

Category: Clinical Trials, Pharmaceutical
Posted: May 14, 2024

Kite Pharma
2400 Broadway Santa Monica, CA 90404